Guochun Liao, PhD, MBA

Founder, President & Chief Executive Officer

Guochun Liao brings over 15 years of experience leading and managing multi-discipline teams in large pharmaceutical and small biotechnology startup companies. Prior to founding IDbyDNA, he was the Vice President of Bioinformatics at Centrillion Biosciences. Before that, he was the Head of Computational Genomics and Research Biostatistics at Roche Pharmaceuticals Palo Alto site, where he was responsible for the data management and analysis for the pre-clinical and clinical projects covering a variety of disease biology and functional areas. Guochun has also served as a consulting professor at Stanford University School of Medicine. His scientific work is featured in many patents, peer reviewed publications and on the cover of scientific journals, including Science and Genome Research. Guochun holds a BS in Biophysics from the University of Science and Technology of China, and an MS in Computer Science, a Ph.D. in Genetics and an MBA from the University of California, Berkeley.

Robert Schlaberg, MD, PhD, MPH

Co-Founder, Chief Medical Officer

Robert Schlaberg is an Assistant Professor of Pathology at the University of Utah School of Medicine and a Medical Director at ARUP Laboratories. His research is focused on next-generation sequencing-based infectious disease diagnostics and is supported in part by the Bill & Melinda Gates Foundation. Robert co-developed Taxonomer, the metagenomics data analysis platform, utilized by IDbyDNA as its central technology. Robert received Medical degrees from the Julius-Maximilians-University in Wuerzburg, Germany and a Masters of Public Health from Columbia University where he also trained in clinical pathology and served as Chief Clinical Pathology Resident. Robert is a board certified Clinical Pathologist and Medical Microbiologist.

Stuart Peterson, MBA

Senior Partner, ARTIS Ventures

Stuart Peterson is the Founder, President and Senior Partner of ARTIS Ventures, a San Francisco-based Tech & Bio VC firm that led early-stage investments in media giant YouTube and cancer-curing Stemcentrx. Stuart currently serves on the Board of Directors of Locus BioSciences, a gene editing company focused on the creation of powerful antimicrobials, Versa Networks, the leading vendor in the SD-WAN and SD-Security markets, Crediwatch, a data insights-as-a-service platform for business and enterprises, and TAE Life Sciences, which is bringing Boron Neutron Capture Therapy (BNCT) out of research and it into a widely available first-line targeted cancer therapy. He is also a Board Advisor for Cohesity, an infinitely scalable, intelligent enterprise data storage platform, Aether BioSystems, which is delivering chemicals and materials built with biology, Excision BioTherapeutics, a gene editing company focused on curing deadly viruses like HIV, and Fabric Genomics, a genomic interpretation platform. Stuart has been named to the Forbe’s Midas List, CB Insights and New York Times Top 100 Venture Capitalists, and TechCrunch VC of the Year Finalist. He also currently serves on the Board of Trustees for the SFMOMA.